Cell Reports · 2016 · 449 citations · 38 references
MedicineImmunologyOncologyApoptosisCancer ImmunologyVaccinologyApoptosis In CancerApoptosis ResistanceCancer ImmunotherapyCancer VaccinesCell DeathImmunogenic Cell DeathApoptosis In Cancer ImmunityCell Death In ImmunityDamage-associated Molecular PatternsDendritic Cell ApoptosisImmunogenic Cell Death InductionMaturation BiologyNecroptotic SignalingTumor Antigen Cross-presentation
Successful immunogenic apoptosis in experimental cancer therapy depends on the induction of strong host anti-tumor responses. Given that tumors are often resistant to apoptosis, it is important to identify alternative molecular mechanisms that elicit immunogenic cell death. We have developed a genetic model in which direct dimerization of FADD combined with inducible expression of RIPK3 promotes necroptosis. We report that necroptotic cancer cells release damage-associated molecular patterns and promote maturation of dendritic cells, the cross-priming of cytotoxic T cells, and the production of IFN-γ in response to tumor antigen stimulation. Using both FADD-dependent and FADD-independent RIPK3 induction systems, we demonstrate the efficient vaccination potential of immunogenic necroptotic cells. Our study broadens the current concept of immunogenic cell death and opens doors for the development of new strategies in cancer therapy.
38
Apoptosis, oncosis, and necrosis. An overview of cell death.
Guido Majno, I Joris · PubMed · 1995 · 3.3K citations
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obéid, Antoine Tesnière, François Ghiringhelli et al. · Nature Medicine · 2006 · 3.1K citations
Medicine, Immunology, Oncology +14
Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase
Liming Sun, Huayi Wang, Zhigao Wang et al. · Cell · 2012 · 2.7K citations · Full text